REFILE-Harrow Q4 revenue slightly beats estimates
Overview
Ophthalmic solutions provider's Q4 revenue rose 33% yr/yr, slightly beating analyst expectations
Adjusted EBITDA for Q4 2025 was $24.2 mln, contributing to $61.9 mln for the year
Company forecasts 2026 revenue of $350 mln to $365 mln and adjusted EBITDA of $80 mln to $100 mln
Outlook
Company forecasts 2026 revenue between $350 mln and $365 mln
Harrow projects 2026 adjusted EBITDA between $80 mln and $100 mln
Result Drivers
PRODUCT DEMAND - Strong demand for VEVYE, IHEEZO, and TRIESENCE drove revenue growth, per CEO Mark L. Baum
OPERATING CASH FLOW - Improved operating cash flow driven by better operating leverage and demand growth
Company press release: ID:nGNX35vd43
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Slight Beat* | $89.10 mln | $88.45 mln (8 Analysts) |
Q4 Gross Margin |
| 79.00% |
|
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Harrow Inc is $69.00, about 27.4% above its February 27 closing price of $54.18
The stock recently traded at 40 times the next 12-month earnings vs. a P/E of 32 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
Related Articles
Starbucks (SBUX) Stock in 2026: Is This Dividend Stock a Good Buy Compared to AI Stocks?
After a tough run, Starbucks (SBUX) is entering 2026 with a less complex playbook, the earliest evidence of accelerating sales, and a dividend that compensates shareholders to wait. AI stocks have produced bigger gains but come with higher expectations and are more volatile. For everyone trying to i
Markets Sell Off amid Iran Tensions — But Oil and Defense Stocks Hold Up
TradingKey - Following U.S. and Israeli airstrikes on Iran, investors are watching closely to see how U.S. markets will open on Monday. Early declines in Asia and Europe suggest pressure on equities, yet the sharp surge in oil prices could offer a lifeline for the energy sector.
JPMorgan Warns Hormuz Blockade Risks Oil Shutdown in 25 Days, But How Will the US-Iran Conflict Shape Global Oil Prices?
TradingKey - Following the announcement on the night of February 28 banning all vessels from passing through the Strait of Hormuz, JPMorgan Chase issued a warning: if the Strait of Hormuz is completely blocked, the combined onshore and offshore storage capacity of Middle Eastern oil-producing nation
US-Iran Conflict Ignites, Global Arms Race Heats Up, Will Defense Stocks See a New Round of Gains?
TradingKey - On February 28 local time, the United States and Israel launched joint large-scale airstrikes against Iran, targeting its nuclear facilities, missile industry, and naval forces. This marks another sharp escalation in the conflict following the US military strikes on Iranian nuclear facilities in June last year. The military operation not only exacerbates already strained geopolitical tensions but has also sent shockwaves through global capital markets, which is expected to further boost defense stocks.
U.S.-Iran Conflict Escalates. Strait of Hormuz Shutdown, How Much Room for Oil Prices to Rise?
TradingKey - A sharp escalation in geopolitical risks has directly triggered intense volatility in global crude oil markets. At the market open this Monday, WTI crude oil futures surged by over 11%, and Brent crude opened up 13%, though these gains subsequently narrowed.
